This article examines the diffeomorphometry of magnetic resonance imaging-derived structural markers for the amygdala, in subjects with symptomatic Alzheimer's disease (AD). Using linear mixed-effects models we show differences between those with symptomatic AD and controls. Based on template centered population analysis, the distribution of statistically significant change is seen in both the volume and shape of the amygdala in subjects with symptomatic AD compared with controls. We find that high-dimensional vertex based markers are statistically more significantly discriminating (p < 0.00001) than lower-dimensional markers and volumes, consistent with comparable findings in presymptomatic AD. Using a high-field 7T atlas, significant atrophy was found to be centered in the basomedial and basolateral subregions, with no evidence of centromedial involvement.
Introduction
Magnetic resonance imaging (MRI) studies have substantially advanced our knowledge of brain atrophy in Alzheimer's disease (AD). MRI measures are an indirect reflection of the neuronal injury that occurs in the brain as the AD pathophysiological process evolves. Several MRI measures are known to be altered among individuals with AD dementia or mild cognitive impairment (MCI). In the initial stages of AD, atrophy appears to have a predilection for brain regions in the medial temporal lobe with heavy deposits of neurofibrillary tangles (Arnold et al., 1991; Braak and Braak, 1991; Price and Morris, 1999) . Consistent with this pattern of neurofibrillary pathology, the volume of the entorhinal cortex and hippocampus have been shown to discriminate patients with AD dementia or MCI versus cognitively normal subjects and to be associated with likelihood of progression from MCI to AD dementia (Atiya et al., 2003; Kantarci and Jack, 2004) .
To date, most MRI studies of subcortical gray matter nuclei have defined a single measure of structural volume (Bossa et al., 2011; McEvoy et al., 2011; Roh et al., 2011) . Although this has the advantage of being quantitative, it does not give specific information about subregions of atrophied nuclei. This information would be useful to determine whether morphometric results correlate with neuropathologic studies, define better the subregional distribution of atrophy, and correlate pathologic changes with clinical features of AD.
Diffeomorphometry and geodesic positioning in computational anatomy (Miller et al., 2014) for the study of the distribution of functional and structural change in neurodegeneration has already proved to be very powerful. Statistical shape analysis has been useful for studying normal age-related changes in subcortical nuclei, and a number of other diseases (Ashburner et al., 2003; Csernansky et al., 1998 Csernansky et al., , 2000 Qiu et al., 2010; Thompson et al., 2004; Wang et al., 2007) . The study described here follows our previous work (Miller et al., 2013) , in which we used diffeomorphometry to measure subregional atrophy in 3 temporal lobe structures, entorhinal cortex, hippocampus, and amygdala, in subjects with preclinical AD, that is, individuals who were clinically and cognitively normal at the time of their MRI scans. This approach allows for a fine-scale high-dimensional analysis of nonuniform change patterns in the structures and complements coarser measures, such as measures of total volume. Despite its proximity to the hippocampus, relatively little is known about the role of amygdala in MCI and AD. Following earlier histopathologic findings (Arriagada et al., 1992; Herzog and Kemper, 1980; Scott et al., 1991 Scott et al., , 1992 Tsuchiya and Kosaka, 1990) , neuroimaging studies of AD patients suggest that amygdala volume may correlate with that of the hippocampus (Poulin et al., 2011) . Further, recent shape analysis (Cavedo et al., 2011; Qiu et al., 2009) suggests there is substantial atrophy within the amygdala in AD.
The study described here focuses on the examination of the amygdala via diffeomorphometry. By mapping features across coordinate systems, it was possible to identify morphometric changes obtained in 1.5 T scans within high-field 7T parcellations of the amygdala. We demonstrate that the location of statistically significant change is distributed across the core amygdala, including the basolateral and basomedial nuclei, in subjects with symptomatic AD compared with controls.
Methods

Study design
In the present study, known as the BIOCARD study, all subjects were cognitively normal when they were recruited. The mean age of the BIOCARD subjects at baseline was 57.1 years. MRI scans were acquired during the period 1995e2005. The participants have now been followed for up to 17 years. Table 1 provides summary of the demographic characteristics of the subjects.
Selection of participants
A total of 354 individuals were initially enrolled in the study. Recruitment was conducted by the staff of the Geriatric Psychiatry branch of the Intramural Program of the National Institute of Mental Health (NIMH). Subjects were recruited via printed advertisements, articles in local or national media, informational lectures, or word-of-mouth. The study was designed to recruit and follow a cohort of cognitively normal individuals who were primarily in middle age. By design, approximately three quarters of the participants had a first degree relative with dementia of the Alzheimer type. The overarching goal was to identify variables among cognitively normal individuals that could predict the subsequent development of mild to moderate symptoms of AD. Toward that end, subjects were administered a comprehensive neuropsychological battery annually. MRI scans, cerebrospinal fluid, and blood specimens were obtained approximately every 2 years. The study was initiated at the NIMH in 1995 and was stopped in 2005. In 2009, a research team at the Johns Hopkins School of Medicine was jointly funded by the National Institute on Aging (NIA) and NIMH to reestablish the cohort, continue the annual clinical and cognitive assessments, collect blood, and evaluate the previously acquired MRI scans, cerebrospinal fluid, and blood specimens. To the best of our knowledge, this is the only study in participants who were cognitively normal at entry, with this set of measures, and with such a long duration of follow-up.
At baseline, all participants completed a comprehensive evaluation at the Clinical Center of the National Institutes of Health (NIH). This evaluation consisted of a physical and neurologic examination, an electrocardiogram, standard laboratory studies (e.g., complete blood count, vitamin B12, thyroid function, and so forth), and neuropsychological testing. Individuals were excluded from participation if they were cognitively impaired, as determined by cognitive testing, or had significant medical problems such as severe cerebrovascular disease, epilepsy, or alcohol or drug abuse. Five subjects did not meet the entry criteria and were excluded at baseline, leaving a total 349 participants who were followed over time.
MRI assessments
The MRI scans acquired at the NIH were obtained using a standard multimodal protocol using GE 1.5 T scanner. The scanning protocol included localizer scans, axial fast spin echo sequence (repetition time 
Clinical and cognitive assessment
The clinical and cognitive assessments of the participants have been described elsewhere (Moghekar et al., 2013) . The cognitive assessment consisted of a neuropsychological battery covering all major cognitive domains (i.e., memory, executive function, language, spatial ability, attention, and processing speed). A clinical assessment was also conducted annually. This included the following: a physical and neurologic examination, record of medication use, behavioral and mood assessments, family history of dementia, history of symptom onset, and a Clinical Dementia Rating (CDR), based on a semi-structured interview (Hughes et al., 1982; Morris, 1993) .
Consensus diagnoses
Each case included in these analyses has received a consensus diagnosis by the staff of the BIOCARD Clinical Core at Johns Hopkins. This research team included: neurologists, neuropsychologists, research nurses, and research assistants. During the study visit, each subject had received a comprehensive cognitive assessment and a CDR, as well as a comprehensive medical evaluation (including a medical, neurologic, and psychiatric assessment). For the cases with evidence of clinical or cognitive dysfunction, a clinical summary was prepared that included information about demographics, family history of dementia, work history and past history of medical, psychiatric, and neurologic disease, medication use, and results from the neurologic and psychiatric evaluation. The reports of clinical symptoms from the subject and collateral sources, based on the CDR, were summarized, and the results of the neuropsychological testing were reviewed. Thus, the diagnostic process for each case was handled in a similar manner: (1) clinical data were examined pertaining to the medical, neurologic, and psychiatric status of the subject; (2) reports of changes in cognition by the subject and by collateral sources were examined; and (3) decline in cognitive performance was established. These data were used to: (1) determine whether the subject had become cognitively impaired; (2) determine the likely etiology of any impairment; and (3) determine the age at which the clinical symptoms began, based primarily on the reports of clinical symptoms from the subject and from collateral sources. These diagnostic procedures are identical to those implemented in the Alzheimer's Disease Research Centers program, supported by the NIA. It is acknowledged that, as this process is dependent on the clinical and cognitive data available at any one point in time, some subjects who are diagnosed as having MCI may subsequently be diagnosed as normal or as impaired not MCI. This represented 4 of the subjects in the total sample. During the acquisition of the scans at the NIH, 7 subjects were diagnosed with dementia of Alzheimer's type (DAT), and 9 subjects were diagnosed with MCI. We term this set of subjects the "symptomatic" cohort, that is, subjects who had MCI or DAT at the time the scans were taken. Four or more years later, when the study was re-initiated at Johns Hopkins, an additional number of subjects had developed MCI or DAT. During the entire period, 230 subjects continued to be cognitively normal whom we defined as the control group. In the analyses described in the following (Section 2.8.3.4), we included age and gender as covariates to adjust for any differences in these parameters between the groups.
Region-of-interest analysis
Statistical shape analysis requires a preliminary alignment phase, which produces a high-dimensional representation in a fixed coordinate system. A common approach in this framework is to register all shapes to a single one, called the template, defining each anatomy by its position relative to the template. This is achieved via diffeomorphic mapping methods. It is important, in this context, to ensure that the template is as close as possible to the population, and it will be defined as representing the population average.
In each scan, the amygdala was segmented using the landmark region-of-interest template-based Large Deformation Diffeomorphic Metric Mapping (LDDMM) pipeline comparable with previous work (Csernansky et al., 1998; Munn et al., 2007) . A representative elderly cognitively normal subject was selected as the template, and left and right structures were segmented manually. The principal axis was identified by placing the head landmark at the center of the inferior boundary of the entorhinal sulcus (on the most anterior coronal plane showing the limen insula), with the tail landmark placed at the center of the most caudal aspect of the basomedial nucleus (on the most caudal coronal plane showing the amygdala). Equidistant sections were selected perpendicular to this principal axis, with landmarks on each section placed at the dorsal lateral and dorsal medial extent of the amygdala, and at an intermediate point on the dorsal amygdala boundary, as well as at the ventral lateral and ventral medial extents of the amygdala, and intermediate point on ventral amygdala boundary. Please see http://caportal.cis.jhu.edu/ wiki/tutorials/amygdala/amygdala.html for a description of the landmark placements. Inter-rater reliability for 9 scans yielded a mean kappa score of 80.95 for left and right segmentations.
Landmarks encompassing the amygdala were used to calculate a rigid transformation (Umeyama, 1991) between the template followed by LDDMM landmark matching and image matching (Beg et al., 2005) . These transformations were subsequently used to move the template segmentation onto each subject's MR scan yielding segmentations for each subject.
Segmentations were individually inspected, manually corrected where necessary and then converted into triangulated surfaces using the open source iso2mesh software. Fig. 1 shows the amygdala relative to the hippocampus and entorhinal cortex and their embedding in a section in one subject.
Amygdalar nuclei parcellation
A 7T MRI scan of resolution 0.8 mm was used to reconstruct high-field parcellation of the population amygdala. The 7T subject is a 42-year-old male who is healthy by self-report. The subject was scanned using a standard MPRAGE protocol in a Philips Achieva 7.0 T scanner (TR ¼ 4.3 ms, TE ¼ 1.95 ms, flip angle ¼ 7 , FOV ¼ 220 Â 220 Â 180). The amygdala was subdivided into 4 nuclei: lateral, basolateral, basomedial, and centromedial nuclei using definitions based on the Paxino Atlas of the Human Brain (Mai et al., 2004) and illustrated in detail at http://caportal.cis.jhu.edu/wiki/tutorials/amygdala/amygdala.html. Here, R and T are a rotation matrix and a translation vector, respectively; s 1 and s 2 are area forms on S 1 and S 2 , respectively; and w is a soft assignment function defined on S 1 Â S 2 , which is positive and satisfies R S1 wðx 0 ; yÞds 1 ðxÞ ¼ R S2 wðx; y 0 Þds 2 ðy 0 Þ ¼ 1 for all ðx; yÞ˛S 1 Â S 2 . Right subvolumes were flipped before alignment to facilitate comparison of left and right structures in fixed coordinates.
The rigidly aligned volumes were used to generate a population template (Ma et al., 2010) based on a generative shape model, in which an observed surface is modeled as a random deformation of a template with additive noise. Given this model, the population template is estimated from the surface population data using the mode approximation to the EM algorithm, subject to the topology constraints that the population template is a diffeomorphic transformation of a fixed reference shape called the hypertemplate. In the Bayesian viewpoint, the population template is considered as a random deformation of the hypertemplate. The population template becomes the coordinate system and is computed by applying the algorithm to the population of 173 baseline scans and is therefore blind to labels.
LDDMM surface registration
Non-rigid registration between the population template and all surfaces is done via LDDMM surface registration (Vaillant and Glaunes, 2005) which computes a smooth and invertible transformation that deforms the template to a surface that is very close to the target. More precisely, it minimizes a 2-term energy function taking the form
where S temp is the population template surface, S obs is the observed surface, and S def is the deformed population template. The first term, Dist shape , is a geodesic distance in shape space, which computes and optimizes a least-deformation path between 2 surfaces, the distance being given by the optimal deformation cost (Vaillant and Glaunes, 2005) . The second error term computes a norm between surfaces. The construction is based on the representation of surfaces as geometric currents.
Shape statistics
During the preprocessing phase, each subject's left structure was registered to the template, resulting in the computation, at each vertex k of the template surface, and for each subject s, of a deformation marker Y k (s) that measures the expansion and/or atrophy at vertex k in subject s relative to the template. This is defined as the logarithm of the local expansion and/or reduction in surface area around vertex k entailed by template registration and can be interpreted mathematically as a log-jacobian on the population template surface. See Figs. 3e5 for examples of such markers. These markers were then transformed into a sequence of shape indicators at different resolution as follows: 2.8.3.1. High resolution. The vertex Jacobian marker Y k (s), which has 750 dimensions associated to the number of vertices.
Projection on Laplace-Beltrami eigenbasis.
The first 25 eigenvectors of the surface Laplacian are computed (on the population template) and the 25-dimensional projection of the surface log-Jacobian of the deformation.
2.8.3.3. High-field defined subnuclei markers. Four amygdala subfields are defined from the 7T high-resolution images, which are mapped onto the population template using LDDMM surface matching. This transports the labelled high-field template to the population template allowing the labeling of the vertices. The diffeomorphic surface mapping generates the bijection between the 1.5 T population template and the high-field 7T atlas on the continuum of the 3D coordinate system allowing us to transfer the labeled information between the 2 coordinate systems. The templates were highly sampled so that vertices are small, thereby allowing precise transfer of information between the vertices of the 2 coordinate systems as defined by the diffeomorphic bijection as shown in Fig. 2 . The labeled vertices of the subfields are used to develop an integrated Jacobian marker for each of the 4 nuclei basolateral, basomedial, centromedial and lateral. These nuclei will be denoted below as 1, 2, 3 and 4 respectively. This is a 4-dimensional marker shown in Fig. 3 . Note that the values are all positive, indicating that group difference is only associated with atrophy.
Global: logarithm of the structure volume.
2.8.3.4. Linear mixed-effects model. The statistical analyses compared subjects with symptomatic AD (i.e., subjects with MCI and AD dementia) versus cognitively normal individuals. The analyses Fig. 2 . High-field 7T amygdala template (left) mapped into BIOCARD 1.5 T population coordinates (middle); regions correspond to parcellation into 4 subnuclei: basolateral (blue), basomedial (sky-blue), centromedial (caramel) and lateral (red). These nuclei will be denoted below as 1, 2, 3 and 4 respectively. The right column shows a labeling into the 4 subfield parcellation of the 1.5 T population BIOCARD atlas generated by transferring the labels in the closest vertex in the middle column to the 1.5 T coordinate system.
included age, gender, and log intracranial volumes as covariates, and computed statistics at each vertex of the template surface, corrected for multiple comparisons, using permutation tests. Our statistical model is a linear mixed-effects model in which the noise associated with the scans from the same subject is modeled as different than the noise associated cross-sectionally in averaging to the common template. Hence the term "mixed-effects". So we introduce group variables g(s) equal to 1 if subject s belonged a disease group and 0 otherwise. These disease groups will be MCI, AD, MCI þ AD for the symptomatic classification. We then use the linear statistical model defined as.
where s denotes subjects/structure; j represents scan order in the subject's time series; v indexes the multivariate marker (v is between 1 and 1, 4, 7, 25, or 750); Y vj (s) is the vth coordinate of deformation marker for subject s at scan j; a j (s) is the subject's age at scan j; g(s) is the subject's group (control or disease); c(s) and d(s) are covariates and respectively denote the subject's intracranial volume and gender; ε vj (s) represents the noise, modeled as maximum-likelihood. The estimation procedure is iterative and alternates the following 2 steps until convergence (which usually happens after a small number of iterations).
Step 1: Least square estimation, updating all parameters with fixed r. Let n denote the number of subjects, N s the number of scans for subject s, and N the total number of scans (the sum of all N s ). Let d be the number of variables in the linear model (d ¼ 6 in our case) and K the dimension of the shape marker. Rewrite the linear model in the form: 
Then, the least square estimator of q is given by
To estimate the variance, define the residual
Step 2: Update r with all other parameters fixed. Compute, with the notation mentioned previously.
[
Then, b r is defined as the minimizer of.
This minimization has no closed-form solution and must be performed numerically.
Note that this model assumes that r is independent of the shape coordinate, v. Although extending this algorithm to a coordinatedependent parameter would be straightforward, we have preferred not to do so to avoid the computational burden of performing K nonlinear optimization procedures at each step mentioned previously, especially in the context of permutation tests that are used to estimate p-values.
After convergence, the log-likelihood is given by (up to an additive constant)
Analysis with familywise error rates
For each type of shape marker, we perform an omnibus test for the significance of the group variables, by testing the null hypoth-
The test statistic is the likelihood ratio between the compared models. The set of coordinates v for which the null hypothesis is rejected is computed via permutation tests and corrected for multiple comparisons within the shape marker (no correction is made across shape markers, because these are highly correlated).
Letting F denote the log-likelihood ratio, the maximum value over all vertices, F * ¼ max v F v , is compared with those obtained by performing the same computation several times, with group labels randomly assigned to subjects. The p-value is given by the fraction Fig. 3 . Statistically significant family wise error rate (FWER) at 5% significance for the mixed effects modeling of the symptomatic group compared with controls, demonstrating atrophy for left and right amygdala. Left panel shows statistics depicted from medial-rostral aspect; right panel shows depiction from medial-caudal aspect. Statistically, significant vertex coloring given by the natural log of the surface Jacobian b þ b 0 a indexed over the template between the control versus symptomatic groups corrected at the average age. For reference only, shown are entorhinal cortex, hippocampus, and lateral ventricle.
of times the values of F * computed after permutation is larger than the value obtained with the true groups. Similarly, p-values are obtained for the volume except that no multiple testing correction is needed. Permutation testing provides a (conservative) estimate of the set of vertices v on which the null hypothesis is not valid. This set is defined by D ¼ fv : F v ! q Ã g where q * is the 95 percentile of the observed value of F * over the permutations (Nichols and Hayasaka, 2003) . These results are visualized by coloring the vertices that were significant with an atrophy measure defined as Àðb v;0 þ b v ageÞ, where b v;0 ; b v are the coefficients associated to the group variable in the regression model for vertex v, and age is the average age in the considered disease group population.
Results
The results of the mixed effects models comparing the controls and the symptomatic cases, taken together as a group, are shown in Table 2 , which provides the p-values for shape change between the groups, as measured by the high-dimensional shape markers, based on the Jacobian statistics at the vertices and Laplace Beltrami expansions, and the low-dimensional volume markers. As can be seen, the high-dimensional vertex based markers are statistically more significantly discriminating (p < 0.00001) than lower-dimensional markers and volumes. To more easily visualize the location of these significant differences, the p-values are superimposed on a template of the amygdala, showing the location of maximum difference between the groups (see Fig. 4 ). Note that the images show the amount of surface atrophy relative to the template, which is expressed in percentages, 100% meaning no difference with template. The red value of 85% means, in terms of the atrophy measure, there has been a change (a net decrease) of 15% from the original template to the disease group at 85%.
In addition, Fig. 5 shows the location of the significant differences between the controls and the symptomatic cases in relation to the nuclei of the amygdala, using a high-field 7T atlas. Significance is determined at 0.05 familywise error rates, based on Bonferroni bound p < 0. Thus, significant atrophy was centered in the basomedial and basolateral subregions, with no evidence of centromedial involvement. Table 3 provides the p-values for the MCI and the AD dementia cases, taken separately, compared with the controls. The differences between the AD cases and the controls are statistically significant for both left and right hemisphere. The differences between the MCI cases and the controls, while in the same direction, are not significant for all markers.
Discussion
The examination of amygdalar shape analysis in this cohort has revealed volumetric changes as well as non-uniform shape changes in the amygdala in subjects with symptomatic AD. By leveraging a high-field amygdala atlas, significantly atrophied subregions were located specifically in the basomedial and lateral nuclei. This is consistent with the histopathologic findings with the greatest cell packing density loss in the medial region and some loss in the lateral region (Herzog and Kemper, 1980) . It is also interesting that the region of significant atrophy illustrated in Figs. 3e5 is identical to that observed in autopsied amygdala with AD (Scott et al., 1991) , that is, superiorly adjacent to the paralaminar region. The same study showed great loss of "large nerve cells" in the magnocellular regions of the amygdala which is deep inside the basomedial nucleus. This is consistent with the hypothesis that the observed changes in the surface of the basomedial nucleus reflect the underlying changes. Our results can be interpreted in terms of the core and non-core amygdalar parcellations by Price. (1987) , (2003) based on subregions sharing developmental, structural, and functional characteristics. Core amgydala consists of the lateral, basal, and accessory basal nuclei, and the non-core amygdala consists of remaining nuclei including the central, medial, and cortical nuclei (Munn et al., 2007; Sheline et al., 1998) . From a functional standpoint, subnuclei in the core amygdala are associated with a role in emotional processing and storage of emotional memories (LeDoux and Schiller, 2009; Price, 1981) , which provide clues as to how they may be affected in MCI and AD.
The volumetric changes are consistent with those observed in a recent study (Poulin et al., 2011) of 2 large samples of MCI and AD cases. The non-uniform changes in shape may explain the variation in volume in the relatively few neuroimaging studies of amygdala in MCI and AD. The lateral part of the amgydala has also been noted in recent shape analysis by Cavedo et al. (2011) and Qiu et al. (2009) . The former study is pertinent because a diffeomorphic approach was applied to a small sample and a parcellated amygdala atlas albeit at 3T was used.
The diffeomorphometry methods described here enable transfer of the high-field amygdala parcellation ensuring anatomic consistency. This also allows for the explicit testing of statistical significance by a subregion by subregion basis allowing us to demonstrate the significant changes in the affected basolateral regions. The fact that there are significant projections from these regions in amygdala to hippocampus and entorhinal cortex also make it significant in light of our other findings in those structures in previous work (Miller et al., 2013) . Given the temporal lobe circuitry model of the degenerative processes in MCI and AD, future studies will be necessary to correlate shape changes in the amygdala with that in the hippocampus, entorhinal cortex, and other structures. Such expanded studies provide additional biomarkers to that of the hippocampus in the early stages of MCI and AD.
Conclusion
In summary, application of advanced computational anatomy diffeomorphometry methods detected atrophy in basomedial and basolateral regions of the amygdala in patients with symptomatic AD. Despite the small sample size, atrophied subregions of the amygdala could be detected with p-values based on familywise error rates which unlike false discovery rates have the advantage of not requiring additional assumptions on the data such as independence or positive dependence. These findings warrant further investigation in a larger data set.
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